CL2014000291A1 - Vacuna que comprende al menos 30 aminoacidos de un polipeptido de p62/sqstm1 o un acido nucleico que lo codifica; y su uso para el tratamiento y profilaxis del cancer. - Google Patents

Vacuna que comprende al menos 30 aminoacidos de un polipeptido de p62/sqstm1 o un acido nucleico que lo codifica; y su uso para el tratamiento y profilaxis del cancer.

Info

Publication number
CL2014000291A1
CL2014000291A1 CL2014000291A CL2014000291A CL2014000291A1 CL 2014000291 A1 CL2014000291 A1 CL 2014000291A1 CL 2014000291 A CL2014000291 A CL 2014000291A CL 2014000291 A CL2014000291 A CL 2014000291A CL 2014000291 A1 CL2014000291 A1 CL 2014000291A1
Authority
CL
Chile
Prior art keywords
prophylaxis
vaccine
cancer
treatment
nucleic acid
Prior art date
Application number
CL2014000291A
Other languages
English (en)
Inventor
Alexander Shnaider
Franco Venanzi
Michael Sherman
Victor Shifrin
Original Assignee
Curelab Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curelab Oncology Inc filed Critical Curelab Oncology Inc
Publication of CL2014000291A1 publication Critical patent/CL2014000291A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2014000291A 2011-08-08 2014-02-05 Vacuna que comprende al menos 30 aminoacidos de un polipeptido de p62/sqstm1 o un acido nucleico que lo codifica; y su uso para el tratamiento y profilaxis del cancer. CL2014000291A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161521280P 2011-08-08 2011-08-08
RU2012108927 2012-03-11
PCT/US2012/050024 WO2013022991A2 (en) 2011-08-08 2012-08-08 Methods and compositions relating to p62 for the treatment and prophylaxis of cancer

Publications (1)

Publication Number Publication Date
CL2014000291A1 true CL2014000291A1 (es) 2014-08-08

Family

ID=47669212

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000291A CL2014000291A1 (es) 2011-08-08 2014-02-05 Vacuna que comprende al menos 30 aminoacidos de un polipeptido de p62/sqstm1 o un acido nucleico que lo codifica; y su uso para el tratamiento y profilaxis del cancer.

Country Status (14)

Country Link
US (3) US9717781B2 (es)
EP (1) EP2750694B8 (es)
JP (1) JP6193231B2 (es)
KR (1) KR102001582B1 (es)
CN (1) CN103889440A (es)
AU (1) AU2012294454B2 (es)
BR (1) BR112014002817A2 (es)
CA (1) CA2844283C (es)
CL (1) CL2014000291A1 (es)
EA (1) EA026228B1 (es)
IL (1) IL230770A0 (es)
MX (2) MX372754B (es)
SG (1) SG2014008411A (es)
WO (1) WO2013022991A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070197A1 (en) 2015-10-19 2017-04-27 Immunolight, Llc X-ray psoralen activated cancer therapy (x-pact)
US10441810B2 (en) * 2007-04-08 2019-10-15 Immunolight, Llc X-ray psoralen activated cancer therapy (X-PACT)
US9717781B2 (en) * 2011-08-08 2017-08-01 Alexander Shneider Methods and compositions relating to P62 for the treatment and prophylaxis of cancer
US20130345143A1 (en) * 2012-01-31 2013-12-26 Rutgers, The State University Of New Jersey MODULATION OF p62 FUNCTION THROUGH THE PB1 DOMAIN
US20160032005A1 (en) * 2013-03-29 2016-02-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceuticals compositions for treating breast cancers
RU2016128557A (ru) * 2013-12-29 2018-02-01 Кьюрлаб Онколоджи, Инк. МЕТОДЫ И КОМПОЗИЦИИ, СВЯЗАННЫЕ С p62 / SQSTM1, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, АССОЦИИРОВАННЫХ С ВОСПАЛЕНИЕМ
CN105079780B (zh) * 2014-05-04 2020-07-14 中国医学科学院药物研究所 一种特异结合trb3的多肽在治疗腹主动脉瘤中的应用
WO2016082192A1 (zh) * 2014-11-28 2016-06-02 中国医学科学院药物研究所 与trb3蛋白特异性结合的多肽，其筛选方法、鉴定和用途
CN106063928B (zh) * 2015-04-23 2020-07-14 中国医学科学院药物研究所 一种多肽或其衍生物在治疗高血压性心肌肥厚中的应用
WO2016207730A1 (en) * 2015-06-22 2016-12-29 The University Of Oslo Targeting of vaccine antigen to an intracellular compartment
US11725035B2 (en) 2016-08-09 2023-08-15 Stipe Therapeutics Aps Methods of treating a disorder associated with with insufficient stimulator of interferon genes (STING) activity
CN106153922B (zh) * 2016-09-14 2018-03-06 深圳大学 一种结肠癌预后预测标志物及其检测方法
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction
EP3749681A1 (en) * 2018-02-06 2020-12-16 STipe Therapeutics ApS Modulation of p62 and sting activity
WO2020028923A2 (en) * 2018-08-02 2020-02-06 Curelab Oncology, Inc. Compositions and methods relating to p62 for the treatment and prophylaxis of age-related macular degeneration
MX2022004598A (es) * 2019-10-16 2022-09-23 Enterome S A Compuestos inmunogenicos para el tratamiento del cancer suprarrenal.
EP4237431A1 (en) * 2020-12-15 2023-09-06 Centre National de la Recherche Scientifique Sqstm1 and its use in cancer therapy
US12245355B2 (en) 2021-02-19 2025-03-04 Mevion Medical Systems, Inc. Gantry for a particle therapy system
JP2025526526A (ja) * 2021-09-27 2025-08-15 チュアラボ オンコロジー，インコーポレーテッド Ｐ６２（ｓｑｓｔｍ１）をコードするベクターおよびｐ６２（ｓｑｓｔｍ１） タンパク質を含む医薬製剤による間葉系幹細胞の活性の調節による疾患の予防と治療
CN114106207B (zh) * 2022-01-24 2022-04-26 诺未科技（北京）有限公司 Ccl5的用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
WO1988006626A1 (en) 1987-03-02 1988-09-07 Whitehead Institute For Biomedical Research Recombinant mycobacterial vaccine
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
WO1991013157A1 (en) 1990-02-26 1991-09-05 Commonwealth Scientific And Industrial Research Organisation Shuttle plasmid for escherichia coli and mycobacteria
GB9015888D0 (en) 1990-07-19 1990-09-05 Smithkline Biolog Vectors
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5610276A (en) 1991-05-17 1997-03-11 Chiron Corporation Polypeptides and antibodies derived from GAP associated protein, p62
WO1992021376A1 (en) 1991-06-06 1992-12-10 Med Immune, Inc. Induction of ctl responses to foreign antigens expressed in mycobacteria
FR2734826B1 (fr) * 1995-06-01 1997-07-04 Rhone Poulenc Rorer Sa Deltap62, ses variants, sequences nucleiques et leurs utilisations
US5962224A (en) * 1995-12-19 1999-10-05 Dana-Farber Cancer Institute Isolated DNA encoding p62 polypeptides and uses therefor
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
EP1109582A4 (en) 1998-08-18 2004-11-03 Res Dev Foundation METHOD FOR STRENGTHENING AND RESTRICTING GENE EXPRESSION
AU2001272932A1 (en) 2000-06-02 2001-12-17 Entremed, Inc Angiostatin and endostatin binding proteins and methods of use
US20030232399A1 (en) 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
EP1506228B1 (en) * 2002-05-14 2009-01-21 Jaekyoon Shin Role of p62 in aging-related disease
JP2008502588A (ja) * 2003-12-12 2008-01-31 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５調節物質及びその使用
US8444973B2 (en) * 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
EP2221063A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
PT2769737T (pt) * 2009-07-20 2017-06-29 Bristol Myers Squibb Co Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas
JP5814128B2 (ja) * 2010-01-07 2015-11-17 公益財団法人東京都医学総合研究所 肝疾患治療薬
US9717781B2 (en) * 2011-08-08 2017-08-01 Alexander Shneider Methods and compositions relating to P62 for the treatment and prophylaxis of cancer

Also Published As

Publication number Publication date
MX353299B (es) 2018-01-08
WO2013022991A2 (en) 2013-02-14
BR112014002817A2 (pt) 2021-09-08
US20140161824A1 (en) 2014-06-12
EP2750694A2 (en) 2014-07-09
CA2844283A1 (en) 2013-02-14
KR102001582B1 (ko) 2019-07-18
MX2014001418A (es) 2014-09-15
JP2014527053A (ja) 2014-10-09
US9717781B2 (en) 2017-08-01
CA2844283C (en) 2024-06-04
WO2013022991A3 (en) 2013-04-18
JP6193231B2 (ja) 2017-09-06
IL230770A0 (en) 2014-03-31
EA026228B1 (ru) 2017-03-31
US10716837B2 (en) 2020-07-21
EP2750694B1 (en) 2018-09-19
EP2750694B8 (en) 2018-11-14
US20200338176A1 (en) 2020-10-29
HK1200086A1 (en) 2015-07-31
AU2012294454B2 (en) 2017-02-02
KR20140083976A (ko) 2014-07-04
MX372754B (es) 2020-06-29
US20170043002A1 (en) 2017-02-16
EA201490423A1 (ru) 2014-07-30
EP2750694A4 (en) 2015-04-15
CN103889440A (zh) 2014-06-25
AU2012294454A1 (en) 2014-02-13
SG2014008411A (en) 2014-03-28

Similar Documents

Publication Publication Date Title
CL2015001442A1 (es) Metodo para tratar enfermedades pulmonares que comprende el uso de compuestos derivados del acido obeticolico.
CL2014000630A1 (es) Una composicion que comprende 1) un compuesto derivado de nucleosido denominado como compuesto 10 y 2) un compuesto derivado de acido 5-tiofeno-2-carboxilico denominado como compuesto 5 o un compuesto derivado del ester metilico del acido carbamico denominado como compuesto 6; y su uso para el tratamiento profilactico o terapeutico de una infeccion por vhc.
CL2014001956A1 (es) Compuestos derivados de beta-lactamicos sustituidos con amidina; metodo para su preparacion; medicamento que los comprende; y su uso para el tratamiento y/o profilaxis de infecciones bacterianas.
CL2014000311A1 (es) Compuestos derivados de benzotiazepinas sustituidas; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis de la infeccion del virus sincicial respiratorio.
CL2015000482A1 (es) Compuestos derivado de 6-aminoacido-heteriarildihidropirimidinas; proceso de obtención; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la infección por el virus de la hepatitis b
BR112014010179A8 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
PT2852391T (pt) Sistemas para tratamento de infeções pulmonares
IL232046A0 (en) Purine derivatives for the treatment of viral infections
CO7071129A2 (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
DK2945642T3 (da) Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
CO6791571A2 (es) Moduladores de la proteína tirosina quinasa 7 (ptk7) para el tratamiento diagnóstico o profilaxis de trastornos neoplásicos
ES2860688T8 (es) Pirrolopirimidinas para uso en la infección por el virus de la gripe
IL251571B (en) Variable proteins comprising the cry1da1 amino acid sequence are activated by lepidopteran
CL2013002908A1 (es) Uso de compuestos derivados de bencimidazol-4-carboxamida para el tratamiento profilactico de la neuropatia periferica inducida por quimioterapia .
ES2897914T8 (es) Compuestos que contienen nitrógeno, adecuados para el uso en la producción de poliuretanos
IL250646A0 (en) A process for conjugating a peptide or protein with a reagent containing a leaving group that includes a peg moiety
BR112014021927A2 (pt) composição farmacêutica antirretroviral, processo para preparar uma composição farmacêutica antirretroviral, método para o tratamento ou profilaxia de doenças causadas por retrovírus, e, uso de lamivudina, festinavir e nevirapina
PL3978074T3 (pl) Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1
EP3223809A4 (en) Amino acid compositions for the treatment of symptoms of disease
IT201700070951A1 (it) Associazione comprendente ossigeno ed acido ialuronico per uso topico-vaginale